{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:24Z","timestamp":1790679204693,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T00:00:00Z","timestamp":1445472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T00:00:00Z","timestamp":1445472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Genet"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/jhg.2015.123","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T06:22:21Z","timestamp":1445494941000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease"],"prefix":"10.1038","volume":"61","author":[{"given":"Younhee","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CheolHo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong Hee","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geu-Ru","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Kun","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,22]]},"reference":[{"key":"BFjhg2015123_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L. & Laster, L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. 276, 1163\u20131167 (1967).","journal-title":"N. Engl. J. Med."},{"key":"BFjhg2015123_CR2","unstructured":"Pollack, A . in The New York Times. Genzyme Drug Shortage Leaves Users Feeling Betrayed (2010). http:\/\/www.nytimes.com\/2010\/04\/16\/business\/16genzyme.html. Accessed on 13 March 2015."},{"key":"BFjhg2015123_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ymgme.2013.03.008","volume":"109","author":"MG Bouwman","year":"2013","unstructured":"Bouwman, M. G., de Ru, M. H., Linthorst, G.E., Hollak, C.E., Wijburg, F.A. & van Zwieten, M. C. Fabry patients' experiences with the timing of diagnosis relevant for the discussion on newborn screening. Mol. Genet. Metab. 109, 201\u2013207 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2015123_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes, D. A., Elliott, P. M., Shah, J., Zuckerman, J., Coghlan, G., Brookes, J. et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94, 153\u2013158 (2008).","journal-title":"Heart"},{"key":"BFjhg2015123_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain, D. P., Waldek, S., Banikazemi, M., Bushinsky, D. A., Charrow, J., Desnick, R. J. et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 18, 1547\u20131557 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFjhg2015123_CR6","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann, R., Kopp, J. B., Austin, H. A. 3rd, Sabnis, S., Moore, D. F., Weibel, T. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285, 2743\u20132749 (2001).","journal-title":"JAMA"},{"key":"BFjhg2015123_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng, C. M., Banikazemi, M., Gordon, R. E., Goldman, M., Phelps, R., Kim, L. et al. A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68, 711\u2013722 (2001).","journal-title":"Am. J. Hum. Genet."},{"key":"BFjhg2015123_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann, R., Ries, M., Timmons, M., Flaherty, J. T. & Brady, R. O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant. 21, 345\u2013354 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFjhg2015123_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","volume":"23","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann, B., Beck, M., Sunder-Plassmann, G., Borsini, W., Ricci, R., Mehta, A. et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\u2014a retrospective analysis from the Fabry Outcome Survey. Clin. J. Pain 23, 535\u2013542 (2007).","journal-title":"Clin. J. Pain"},{"key":"BFjhg2015123_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.chroma.2015.01.004","volume":"1381","author":"SK Byeon","year":"2015","unstructured":"Byeon, S. K., Lee, J. Y., Lee, J. S. & Moon, M. H. Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1381, 132\u2013139 (2015).","journal-title":"J. Chromatogr. A"},{"key":"BFjhg2015123_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13023-014-0169-6","volume":"9","author":"R Schiffmann","year":"2014","unstructured":"Schiffmann, R., Pastores, G. M., Lien, Y. H., Castaneda, V., Chang, P., Martin, R. et al. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study. Orphanet J. Rare Dis. 9, 169 (2014).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFjhg2015123_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","volume":"114","author":"S Ferreira","year":"2015","unstructured":"Ferreira, S., Ortiz, A., Germain, D. P., Viana-Baptista, M., Caldeira-Gomes, A., Camprecios, M. et al. The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. Mol. Genet. Metab. 114, 248\u2013258 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2015123_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ymgme.2013.07.005","volume":"110","author":"M Furujo","year":"2013","unstructured":"Furujo, M., Kubo, T., Kobayashi, M. & Ohashi, T. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain. Mol. Genet. Metab. 110, 405\u2013410 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2015123_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","volume":"12","author":"O Lidove","year":"2010","unstructured":"Lidove, O., West, M. L., Pintos-Morell, G., Reisin, R., Nicholls, K., Figuera, L. E. et al. Effects of enzyme replacement therapy in Fabry disease\u2014a comprehensive review of the medical literature. Genet. Med. 12, 668\u2013679 (2010).","journal-title":"Genet. Med."},{"key":"BFjhg2015123_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach, S. M., Smid, B. E., Bouwman, M. G., Linthorst, G. E., Dijkgraaf, M. G. & Hollak, C. E. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J. Rare Dis. 8, 47 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFjhg2015123_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1750-1172-8-29","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach, S. M., Hollak, C. E., Linthorst, G. E. & Dijkgraaf, M. G. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J. Rare Dis. 8, 29 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFjhg2015123_CR17","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta, A., Beck, M., Elliott, P., Giugliani, R., Linhart, A., Sunder-Plassmann, G. et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374, 1986\u20131996 (2009).","journal-title":"Lancet"},{"key":"BFjhg2015123_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","volume":"94","author":"AC Vedder","year":"2008","unstructured":"Vedder, A. C., Breunig, F., Donker-Koopman, W. E., Mills, K., Young, E., Winchester, B. et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol. Genet. Metab. 94, 319\u2013325 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2015123_CR19","doi-asserted-by":"publisher","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","volume":"7","author":"SM Rombach","year":"2012","unstructured":"Rombach, S. M., Aerts, J. M., Poorthuis, B. J., Groener, J. E., Donker-Koopman, W., Hendriks, E. et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE 7, e47805 (2012).","journal-title":"PLoS ONE"},{"key":"BFjhg2015123_CR20","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst, G. E., Hollak, C. E., Donker-Koopman, W. E., Strijland, A. & Aerts, J. M. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 66, 1589\u20131595 (2004).","journal-title":"Kidney Int."},{"key":"BFjhg2015123_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","volume":"96","author":"B Benichou","year":"2009","unstructured":"Benichou, B., Goyal, S., Sung, C., Norfleet, A. M. & O'Brien, F. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol. Genet. Metab. 96, 4\u201312 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2015123_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2008.10.013","volume":"96","author":"CE Hollak","year":"2009","unstructured":"Hollak, C. E. & Linthorst, G. E. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? Mol. Genet. Metab. 96, 1\u20133 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"BFjhg2015123_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13023-014-0195-4","volume":"10","author":"ED Kakkis","year":"2015","unstructured":"Kakkis, E. D., O'Donovan, M., Cox, G., Hayes, M., Goodsaid, F., Tandon, P. K. et al. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints. Orphanet J. Rare Dis. 10, 16 (2015).","journal-title":"Orphanet J. Rare Dis."},{"key":"BFjhg2015123_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1101\/gr.103697.109","volume":"20","author":"MF Berger","year":"2010","unstructured":"Berger, M. F., Levin, J. Z., Vijayendran, K., Sivachenko, A., Adiconis, X., Maguire, J. et al. Integrative analysis of the melanoma transcriptome. Genome Res. 20, 413\u2013427 (2010).","journal-title":"Genome Res."},{"key":"BFjhg2015123_CR25","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1073\/pnas.1222897110","volume":"110","author":"Y Ko","year":"2013","unstructured":"Ko, Y., Ament, S. A., Eddy, J. A., Caballero, J., Earls, J. C., Hood, L. et al. Cell type-specific genes show striking and distinct patterns of spatial expression in the mouse brain. Proc. Natl Acad. Sci. USA 110, 3095\u20133100 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFjhg2015123_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"BFjhg2015123_CR27","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","volume":"25","author":"C Trapnell","year":"2009","unstructured":"Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105\u20131111 (2009).","journal-title":"Bioinformatics"},{"key":"BFjhg2015123_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/bib\/bbs046","volume":"14","author":"MA Dillies","year":"2013","unstructured":"Dillies, M.A., Rau, A., Aubert, J., Hennequet-Antier, C., Jeanmougin, M., Servant, N. et al. A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis. Brief. Bioinform. 14, 671\u2013683 (2013).","journal-title":"Brief. Bioinform."},{"key":"BFjhg2015123_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"BFjhg2015123_CR30","doi-asserted-by":"publisher","first-page":"R183","DOI":"10.1186\/gb-2007-8-9-r183","volume":"8","author":"DW Huang","year":"2007","unstructured":"Huang, D. W., Sherman, B. T., Tan, Q., Collins, J. R., Alvord, W. G., Roayaei, J. et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8, R183 (2007).","journal-title":"Genome Biol."},{"key":"BFjhg2015123_CR31","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFjhg2015123_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini, G. B., Vanzin, C. S., Rodrigues, D. B., Deon, M., Ribas, G. S., Barschak, A. G. et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim. Biophys. Acta 1822, 226\u2013232 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFjhg2015123_CR33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1101\/gr.118992.110","volume":"21","author":"I Lee","year":"2011","unstructured":"Lee, I., Blom, U. M., Wang, P. I., Shim, J. E. & Marcotte, E. M. Prioritizing candidate disease genes by network-based boosting of genome-wide association data. Genome Res. 21, 1109\u20131121 (2011).","journal-title":"Genome Res."},{"key":"BFjhg2015123_CR34","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","volume":"274","author":"JQ Fan","year":"2007","unstructured":"Fan, J. Q. & Ishii, S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J. 274, 4962\u20134971 (2007).","journal-title":"FEBS J."},{"key":"BFjhg2015123_CR35","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot, K. D., Holmes, A. & Miners, A. H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet. 38, 769\u2013775 (2001).","journal-title":"J. Med. Genet."}],"container-title":["Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/jhg2015123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhg2015123","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhg2015123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:33:49Z","timestamp":1684431229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhg2015123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,22]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFjhg2015123"],"URL":"https:\/\/doi.org\/10.1038\/jhg.2015.123","relation":{},"ISSN":["1434-5161","1435-232X"],"issn-type":[{"value":"1434-5161","type":"print"},{"value":"1435-232X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,22]]},"assertion":[{"value":"28 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}